

Form PTO-1449 (modified)

Atty. Docket No.

GOUD:038US

Serial No.

10/671,340

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Denis Gravel *et al.*

Filing Date:

September 25, 2003

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>ju</i>	A1	5,512,549	4/30/96	Chen <i>et al.</i>	514	12	10/18/94
<i>ju</i>	A2	5,545,618	8/13/96	Buckley <i>et al.</i>	514	12	12/10/93

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>ju</i>	B1	EP 0 733 644	9/25/96	Europe	—	—	English
<i>ju</i>	B2	WO 91/11457	8/08/91	PCT	—	—	English
<i>ju</i>	B3	WO 99/43707	9/02/99	PCT	—	—	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>ju</i>	C1	Adelhorst <i>et al.</i> , "Structure-activity sutides of glucagon-like peptide-1," <i>J. Biol. Chem.</i> , 269(9):6275-6278, 1994.
<i>ju</i>	C2	Burcelin <i>et al.</i> , "Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analogy of glucagon-like peptide-1," <i>Metabolism</i> , 48(2):252-258, 1999.
<i>ju</i>	C3	D'alessio <i>et al.</i> , "Glucagon-like peptide 1 decreases hepatic glucose production independent of insulin and glucagon," <i>Diabetes</i> , 46(suppl 1):29A, 1997.
<i>ju</i>	C4	Deacon <i>et al.</i> , "Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity," <i>Diabetologia</i> , 41:271-278, 1998.
<i>ju</i>	C5	Doyle and Egan, "Glucagon-like peptide-1," <i>Recent Prog. Horm. Res.</i> , 56:377-399, 2001.
<i>ju</i>	C6	Doyle <i>et al.</i> , "Insertion of an N-Terminal 6-amino hexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent," <i>Endocrinology</i> , 142(10):4462-4468, 2001.
<i>ju</i>	C7	Drucker, "Minireview: the glucagon-like peptides," <i>Endocrinology</i> , 142(2):521-527, 2001.

25404463.1

EXAMINER:

Jeffrey E. Russell

DATE CONSIDERED:

January 10, 2005

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

GOUD:038US

10/671,340

List of Patents and Publications for Applicant's

Applicant

Denis Gravel *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 25, 2003

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>gr</i>	C8	Dugas and Penney, In: <i>Bioorganic Chemistry</i> , Springer-Verlag, NY, 54-92, 1981.
<i>gr</i>	C9	Gorrell <i>et al.</i> , "CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes," <i>Scand. J. Immunol.</i> , 54:249-264, 2001.
<i>gr</i>	C10	Gutniak <i>et al.</i> , "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus," <i>The New England Journal of Medicine</i> , 326:1316-1322, 1992.
<i>gr</i>	C11	Gutniak, "Treatment of diabetes GLP-1: a new kid in town," <i>International Diabetes Monitor</i> , 9(2):1-12, 1997.
<i>gr</i>	C12	Holst, "Glucagonlike peptide 1: a newly discovered gastrointestinal hormone," <i>Gastroenterology</i> , 107:1848-1855, 1994.
<i>gr</i>	C13	Holst, "Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signaling nutritional abundance, with an unusual therapeutic potential," <i>Trends Endocrinol. Metab.</i> , 10(6):229-235, 1999.
<i>gr</i>	C14	Holz <i>et al.</i> , "Activation of a cAMP-regulated Ca ²⁺ signaling pathway in pancreatic β -cells by the insulinotropic hormone glucagon-like peptide-1," <i>J. Biol. Chem.</i> , 270(30):17749-17757, 1995.
<i>gr</i>	C15	Kieffer and Habener, "The glucagon-like peptides," <i>Endocrine Reviews</i> , 20(6):876-913, 1999.
<i>gr</i>	C16	Kreymann <i>et al.</i> , "Glucagon-like peptide-1 7-36: a physiological incretin in man," <i>Lancet</i> , 2(8571):1300-1304, 1987.
<i>gr</i>	C17	Merrifield, "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," <i>Chem. Soc.</i> , 85:2149-2154, 1962.
<i>gr</i>	C18	Nauck <i>et al.</i> , "Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes," <i>Diabetologia</i> , 29:46-52, 1986.
<i>gr</i>	C19	Nauck <i>et al.</i> , "Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36 amide) in type 2 (non-insulin-dependent) diabetic patients," <i>Diabetologia</i> , 36:741-744, 1993.
<i>gr</i>	C20	Nauck, "Glucagonlike peptide 1," <i>Curr. Opin. Endocrinol. Diabet.</i> , 4:291-299, 1997.
<i>gr</i>	C21	Peptide synthesis protocols, <i>Methods in molecular biology</i> , Vol. 35, Pennington and Dunn (eds.), Humana Press, 1994.

25404463.1

EXAMINER: Jeffrey E. Russel

DATE CONSIDERED: January 10, 2005

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. GOUD:038US	Serial No. 10/671,340
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Denis Gravel <i>et al.</i>	
		Filing Date: September 25, 2003	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>JA</i>	C22	Perfetti and Merkel, "Glucagon-like peptide-1: a major regulator of pancreatic β -cell function," <i>European Journal of Endocrinology</i> , 143:717-725, 2000.
<i>JA</i>	C23	<i>Remington's Pharmaceutical Sciences</i> , 15 th ed., 33:624-652, Mack Publishing Company, Easton, PA, 1980.
<i>JA</i>	C24	Scrocchi <i>et al.</i> , "Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene," <i>Nature Medicine</i> , 2(11):1254-1258, 1996.
<i>JA</i>	C25	Siegel <i>et al.</i> , "Biological activity of GLP-1-analogues with N-terminal modifications," <i>Regulatory Peptides</i> , 79:93-102, 1999.
<i>JA</i>	C26	Stewart and Young, In: <i>Solid Phase Peptide Synthesis</i> , 24-66, Freeman, San Francisco, 1969.
<i>JA</i>	C27	Suzuki <i>et al.</i> , "Effects of GLP-1 and its fragment peptides on pancreatic hormone release," <i>Diabetes Res.</i> , 5(Suppl 1):S30, 1988.
<i>JA</i>	C28	Toft-Nielsen <i>et al.</i> , "Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients," <i>Diabetes Care</i> , 22:1137-1143, 1999.
<i>JA</i>	C29	Tolessa <i>et al.</i> , "Inhibitory effect of glucagon-like peptide-1 on small bowel motility," <i>J. Clin. Invest.</i> , 102(4):764-774, 1998.
<i>JA</i>	C30	Wang <i>et al.</i> , "Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats," <i>J. Clin. Invest.</i> , 99(12):2883-2889, 1997.
<i>JA</i>	C31	Xiao <i>et al.</i> , "Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo," <i>Biochemistry</i> , 40:2860-2869, 2001.
<i>JA</i>	C32	Xu <i>et al.</i> , "Exendin-4 stimulates both β -cell replication and neogenesis, resulting in increased β -cell mass and improved glucose tolerance in diabetic rats," <i>Diabetes</i> , 48:2270-2276, 1999.

25404463.1

EXAMINER: *Jeffrey E. Russel* | DATE CONSIDERED: *January 10, 2005*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

GOUD:038US

Serial No.

10/671,340

Applicant

Denis Gravel *et al.*

Filing Date:

September 25, 2003

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>JK</i>	B4	WO 00/55119	9/21/00	PCT			English
<i>JK</i>	B5	WO 02/10195	2/07/02	PCT			English
<i>JK</i>	B6	WO 98/08871	3/05/98	PCT			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25433356.1

EXAMINER: *Jeffrey E. Russel*DATE CONSIDERED: *January 10, 2005*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)